Sun, Dec 28, 2014, 9:40 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

  • breakoutpicks breakoutpicks Apr 13, 2014 1:50 PM Flag

    ROCHE COULD LEAPFROG THE INDUSTRY AND BUY THE MOST ADVANCED STEM CELL COMPANY THAT IS EXTREMELY UNDERVALUED AND OVERSOLD

    UNRIVALED AND PROVEN trial results demonstrate that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

 
RHHBY
34.225-0.055(-0.16%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.